ERBB2 and non-small cell lung carcinoma: It is approved in Non-small cell lung cancer (NSCLC) (55% objective response among 91 patients) based on the DESTINY-Lung01 for patients with ERBB2 kinase domain mutations (40) and in metastatic breast cancer for patients with HER2 low expression by IHC (41).